NCT07220512 The Better, Harder, Faster, Stronger Study
| NCT ID | NCT07220512 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Frailty at Older Adults |
| Study Type | OBSERVATIONAL |
| Enrollment | 35 participants |
| Start Date | 2025-07-28 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35 participants in total. It began in 2025-07-28 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.
Eligibility Criteria
Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent. * Age \> 55 years at the time of enrollment. * Newly diagnosed suspected ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator. * Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter. * Ability to read, understand, and write the English language. * As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: * History of brain metastases. * History of poorly controlled psychiatric conditions, defined as hospitalization within the prior 3 months for psychiatric disorders, traumatic brain injury, cerebrovascular event, or dementia, per the enrolling investigator. * Use of anti-amyloid agents, cholinesterase inhibitors, or glutamate regulators at the time of enrollment. * Vision impairment that would impede completion of study assessments, per enrolling investigator.
Contact & Investigator
Anna Kuan-Celarier, MD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT07220512 clinical trial?
This trial is open to female participants only, aged 55 Years or older, studying Frailty at Older Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07220512 currently recruiting?
Yes, NCT07220512 is actively recruiting participants. Contact the research team at sydney.mcentire@advocatehealth.org for enrollment information.
Where is the NCT07220512 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT07220512 clinical trial?
NCT07220512 is sponsored by Wake Forest University Health Sciences. The principal investigator is Anna Kuan-Celarier, MD at Wake Forest University Health Sciences. The trial plans to enroll 35 participants.